Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI). It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INVA
Previous SymbolNASDAQ:THRX
CUSIP88338T10
Phone650-238-9600
Debt
Debt-to-Equity RatioN/A
Current Ratio28.23
Quick Ratio28.23
Price-To-Earnings
Trailing P/E Ratio14.37
Forward P/E Ratio8.80
P/E GrowthN/A
Sales & Book Value
Annual Sales$217.22 million
Price / Sales7.82
Cash Flow$1.4343 per share
Price / Cash Flow11.72
Book Value($2.38) per share
Price / Book-7.06
Profitability
EPS (Most Recent Fiscal Year)$1.17
Net Income$134.14 million
Net Margins75.67%
Return on Equity-110.01%
Return on Assets62.76%
Miscellaneous
Employees12
Outstanding Shares101,040,000
Market Cap$1.78 billion
OptionableOptionable
Innoviva (NASDAQ:INVA) Frequently Asked Questions
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
How were Innoviva's earnings last quarter?
Innoviva Inc (NASDAQ:INVA) issued its quarterly earnings data on Wednesday, October, 31st. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.49 by $0.06. The biotechnology company had revenue of $61.70 million for the quarter, compared to analysts' expectations of $64 million. Innoviva had a negative return on equity of 110.01% and a net margin of 75.67%. The business's revenue for the quarter was up 27.0% on a year-over-year basis. During the same period last year, the company posted $0.21 EPS. View Innoviva's Earnings History.
When is Innoviva's next earnings date?
What price target have analysts set for INVA?
2 brokerages have issued 12-month price objectives for Innoviva's stock. Their forecasts range from $16.00 to $16.00. On average, they expect Innoviva's share price to reach $16.00 in the next year. This suggests that the stock has a possible downside of 4.8%. View Analyst Price Targets for Innoviva.
What is the consensus analysts' recommendation for Innoviva?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innoviva.
Has Innoviva been receiving favorable news coverage?
Media headlines about INVA stock have been trending somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innoviva earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.
Are investors shorting Innoviva?
Innoviva saw a increase in short interest in the month of November. As of November 30th, there was short interest totalling 17,516,123 shares, an increase of 10.7% from the November 15th total of 15,821,357 shares. Based on an average daily volume of 1,488,031 shares, the short-interest ratio is currently 11.8 days. Approximately 26.4% of the company's shares are short sold. View Innoviva's Current Options Chain.
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Alkermes (ALKS), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Catalent (CTLT), SAGE Therapeutics (SAGE), Amneal Pharmaceuticals (AMRX), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO) and FibroGen (FGEN).
Who are Innoviva's key executives?
Innoviva's management team includes the folowing people:
- Mr. Geoffrey Hulme, Interim Principal Exec. Officer
- Ms. Marianne Zhen, Chief Accounting Officer & Principal Accounting Officer (Age 49)
- Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
- Dr. Kevin Kwok, Head of Talent Acquisition & Strategy
- Dr. Edmund J. Moran Ph.D., VP and R&D Program Leader (Age 57)
Who are Innoviva's major shareholders?
Innoviva's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.71%), Vanguard Group Inc. (6.94%), Vanguard Group Inc (6.94%), Renaissance Technologies LLC (4.65%), Dimensional Fund Advisors LP (2.12%) and LSV Asset Management (1.76%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar and Theodore J Jr Witek. View Institutional Ownership Trends for Innoviva.
Which major investors are selling Innoviva stock?
INVA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Acadian Asset Management LLC, Algert Global LLC, First Trust Advisors LP, James Investment Research Inc., AQR Capital Management LLC, American Century Companies Inc. and Hussman Strategic Advisors Inc.. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie and Theodore J Jr Witek. View Insider Buying and Selling for Innoviva.
Which major investors are buying Innoviva stock?
INVA stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, LSV Asset Management, JPMorgan Chase & Co., JPMorgan Chase & Co., WINTON GROUP Ltd, MERIAN GLOBAL INVESTORS UK Ltd, Deutsche Bank AG and Schroder Investment Management Group. View Insider Buying and Selling for Innoviva.
How do I buy shares of Innoviva?
Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innoviva's stock price today?
One share of INVA stock can currently be purchased for approximately $16.81.
How big of a company is Innoviva?
Innoviva has a market capitalization of $1.78 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.
What is Innoviva's official website?
How can I contact Innoviva?
Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]
MarketBeat Community Rating for Innoviva (NASDAQ INVA)
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
